Five Prime Therapeutics is cutting its headcount by 20 percent, part of a cash-saving effort the company is making to focus on the cancer drugs it has already advanced into clinical trials. South San Francisco, CA-based Five Prime (NASDAQ: FPRX) said Tuesday that the corporate restructuring will reduce operating expenses by $10 million in 2019 […]
Original Article: Five Prime’s Shakeup Cuts Staff 20%, Keeps Focus on Clinical Programs